Abstract #0472
Exploring the inherent CEST MRI signal of anticancer drug gemcitabine
Yuguo Li 1,2 , Kannie Chan 1,2 , peter van Zijl 1,2 , Bert Vogelstein 3 , Michael McMahon 1,2 , Shibin Zhou 3 , and Guanshu Liu 1,2
1
Radiology, Johns Hopkins University School
of Medicine, Baltimore, MD, United States,
2
FM
Kirby center, Kennedy Krieger Institute, Baltimore, MD,
United States,
3
Ludwig
Center, Howard Hughes Medical Institute and Sidney
Kimmel Cancer Center, Johns Hopkins University School of
Medicine, Baltimore, MD, United States
Non-invasive tracking of drug delivery is of great
clinical interest. Herein, we explored a direct way to
track liposome mediated delivery of gemcitabine, a
first-line drug for treating pancreatic cancer. We show
that this can be achieved using its inherent Chemical
Exchange Saturation Transfer (CEST) MRI signal at 2.1
and 1.0 ppm originating from the exchangeable amino and
hydroxyl protons, respectively. Unlike traditional
approaches, the CEST MRI detection doesnt require the
use of extra contrast agents, and is able to directly
convert the gemcitabine-loaded nanoparticle drug
delivery system into a theranostic system.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
